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Abstract
Background: Tuberculosis is a major cause of morbidity and mortality globally. Recent scholarly
attention to public health ethics provides an opportunity to analyze several ethical issues raised by
the global tuberculosis pandemic.
Discussion: Recently articulated frameworks for public health ethics emphasize the importance of
effectiveness in the justification of public health action. This paper critically reviews the relationship
between these frameworks and the published evidence of effectiveness of tuberculosis
interventions, with a specific focus on the controversies engendered by the endorsement of
programs of service delivery that emphasize direct observation of therapy. The role of global
economic inequities in perpetuating the tuberculosis pandemic is also discussed.
Summary: Tuberculosis is a complex but well understood disease that raises important ethical
challenges for emerging frameworks in public health ethics. The exact role of effectiveness as a
criterion for judging the ethics of interventions needs greater discussion and analysis. Emerging
frameworks are silent about the economic conditions contributing to the global burden of illness
associated with tuberculosis and this requires remediation.
Background
As a disease with a known causal agent, pathogenesis,
mode of transmission and predisposing factors, as well as
an effective cure, the goal of eradication of tuberculosis
(TB) should be a plausible one [1]. The decline of TB in
the developed world in the mid to late 20th century gave
rise to an expectation that this could be achieved. How-
ever, with changing socioeconomic conditions and the
arrival of HIV/AIDS came an increase in the number of TB
cases, a much higher risk of active (and therefore, commu-
nicable) TB, and the emergence of strains of TB resistant
to available treatments and more likely to cause death.
At present TB is the world's leading infectious killer; 8 mil-
lion people annually develop active disease and 2 million
die from their disease [2]. The most vulnerable popula-
tions remain the poor, the homeless, people in and from
developing nations, those with HIV infections, substance
abusers and the prison population. As such, it is a highly
stigmatized illness, and those most often affected have the
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most limited access to necessary resources. Since TB
regained its alarming profile and was declared a global
emergency by the World Health Organization, there have
been renewed and concentrated efforts for its control.
This renewed effort raises important issues relating to the
just and humane treatment of persons with tuberculosis
infections. This paper will discuss ethical issues in the con-
trol of tuberculosis. The paper will analyze the problem-
atic issues entailed in the relationship between the
effectiveness of therapy and justifications for the limita-
tion of individual autonomy as applied in tuberculosis
control. The analysis will draw on recent frameworks for
the analysis of ethical issues in public health and stand-
ards of evidence assessment as articulated by proponents
of evidence based medicine. Finally, the ethical implica-
tions of global inequities in health will be discussed as
they relate to tuberculosis.
Discussion
Ethics
Efforts to control TB involve unique social and cultural
concerns [3] as well as complex ethical considerations
involving medical and public health ethics [4,5]. Tradi-
tional medical ethics focuses on the physician-patient
relationship, and the preservation of autonomy and
human dignity, and is very strongly individualistic in per-
spective. Public health ethics, on the other hand, focuses
on populations and the protection and promotion of
health in communities.
Tuberculosis control raises several issues including stig-
matization of infected individuals, and the cultural [6]
and economic consequences of acquiring TB [7,8]. One
central ethical problem concerning TB control consists of
balancing the patient's rights and autonomy with the pro-
tection of the public's health [9]. Interventions such as
directly observed therapy, detention and mandatory treat-
ment entail a substantial reduction of autonomy not cus-
tomarily found in clinical medicine. On a larger scale, TB
is also a human rights issue, raising important questions
about equity regarding who suffers the most from disease,
and the global imbalance with regard to disease burden as
well as reciprocal social obligation to alleviate suffering
[10]. Therefore, the evidential standard supporting tuber-
culosis intervention should be high, in order for interven-
tions that infringe human rights to be justified both
scientifically and ethically.
Individual rights vs. public health
Given its nature and impact, TB is indeed a serious threat
to communities, which deserve protection from exposure
to TB and attention to the means to curtail its spread.
Simultaneously, individuals within communities, particu-
larly those in liberal democracies, have the right to per-
sonal autonomy and privacy. Achieving a balance
between these seemingly conflicting goals can only result
from an understanding of the underlying ethical princi-
ples [11]. It is possible to justify breaches of civil liberty
when the goal is to prevent harm to the community, and
the means to achieve this end are ethically and legally
appropriate [12]. However, if individuals are required to
sacrifice their autonomy for the good of the community,
then it is the community's responsibility to attend to the
individual's health requirements and to support and facil-
itate the discharge of the individual's obligations [13].
Public health ethics
There has been a recent expanded interest in the relation-
ship between public health and ethics. In the last years,
several commentators have provided frameworks for the
analysis of ethical issues in public health. As tuberculosis
control is one of the primary concerns, both of historic
and modern public health, it is instructive to see the
extent to which the frameworks articulated for public
health ethics match up with the current provision of
tuberculosis care. In particular, two frameworks will be
evaluated in terms of their relationship to tuberculosis
and ethics.
Nancy Kass, in the American Journal of Public Health,
articulated an ethics framework for public health [14]. In
this framework, there are six primary questions that need
to be answered.
1. What are the public health goals of the proposed pro-
gram?
2. How effective is the program in achieving its stated
goals?
3. What are the potential burdens of the program?
4. Can burdens be minimized or are there alternative
approaches?
5. Is the program implemented fairly?
6. How can the burdens of the program be fairly bal-
anced?
A second framework articulated by Childress et al. enu-
merate five considerations that need to be weighed when
considering the ethical dimensions of public health action
[15]. These include effectiveness, proportionality, neces-
sity, least infringement and public justification.
Both of these frameworks share significant overlap but it
is important to note that among the primary considera-
tions in each of these frameworks are effectiveness andBMC Medical Ethics 2004, 5 http://www.biomedcentral.com/1472-6939/5/2
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what can be termed least restrictive means. Effectiveness
in these frameworks relates to the published scientific evi-
dence indicating that any proposed intervention will do
more good than harm. Neither framework states a stand-
ard of effectiveness that should be met. Kass writes: "As a
rule of thumb, the greater the burdens posed by a [public
health] program – for example, in terms of cost, con-
straints on liberty, or targeting particular, already vulnera-
ble segments of the population – the stronger the
evidence must be to demonstrate that the program will
achieve its goals" [14].
The concept of an evidence hierarchy as articulated by
proponents of evidence based medicine is not mentioned,
but may serve as a useful and increasingly agreed upon
standard of the strength of evidence required to justify a
public health program. Such a hierarchy was initially
introduced as a means of evaluating preventive health
care. Evidence hierarchies regard systematic reviews and
randomized trials as providing stronger evidence than
observational studies and expert opinion [16]. In terms of
tuberculosis management, then, programs that impose
burdens such as curtailing individual freedoms should
come from as high as possible on this evidence hierarchy
in order to be regarded as both scientifically and ethically
justified.
The concept of least infringement or the minimization of
burdens and use of alternative approaches indicate the
need for proportionality of public health response to pub-
lic health problems. This will be discussed below.
The effectiveness of tuberculosis interventions
The empirical research literature on tuberculosis can be
regarded as complementary to an analysis of the ethical
issues. Interventions that have the potential to impede
autonomy or infringe upon established rights should have
evidence of effectiveness. In terms of interventions, it can
be argued that an approach to tuberculosis involving least
restrictive means is an appropriate approach to tuberculo-
sis care. A schema of least restrictive means in tuberculosis
care would entail progression through the following steps.
• Self management
• Directly observed therapy (DOT)
• Provision of a therapeutic milieu
• Detention in a health care setting
Consequently, self-management assures the most auton-
omy and dignity and least intrusion in a person's life,
whereas detention is decidedly autonomy denying. Hence
there should be an evidence gradient with the highest
probable benefits provided for interventions that reduce
or diminish autonomy and voluntariness.
Failure to complete an appropriate course of chemother-
apy for tuberculosis is the chief cause of antibiotic resist-
ance and a substantial cause of morbidity and mortality
from tuberculosis. The successful administration and
completion of a complex antibiotic regimen over pro-
longed periods of time has been problematic. As a conse-
quence treatment regimens and programs incorporating
direct observation as an integral component of chemo-
therapy have been developed and variously called DOT,
or DOTS, when a shorter course of antibiotic therapy is
employed within an overall TB control strategy. Direct
observation, among other program elements is hypothe-
sized to enhance and facilitate adherence and conse-
quently improve treatment outcomes. For the purposes of
our discussion, we are concerned with the requirement of
direct observation of therapy by someone other than the
individual with the disease, and not with the program-
matic aspects of delivery programs such as political com-
mitment, provision of medication, technical support
(such as sputum microscopy) education, etc which argua-
bly could be present for the management of other chronic
and communicable diseases such as coronary artery dis-
ease and HIV/AIDS where patient adherence is problem-
atic and direct observation is not advocated.
This logic underlies the WHO's recommendation of
directly observed therapy as the international method of
TB control and is supported by data reflecting decreased
relapse and resistance rates as a result of its implementa-
tion [17]. A review of the DOTS strategy in six WHO
regions extrapolated that DOTS can reduce deaths by TB
and incidence of infection on the condition that detection
and cure rates improved [18]. However, this analysis
relied upon complex mathematical modeling and projec-
tions, and not only on direct empirical evidence of effec-
tiveness from randomized trials. DOTS implementation
in India in 1993 has lead to a significant increase in case
detection and treatment [19]. Limitations on its success in
India and potentially other low-income countries with
high disease burden include regional discrepancies in the
functioning of health services, and the degree of private
sector regulation. A randomized trial of DOTS in Pakistan
did not demonstrate its superiority over self-administered
treatment, which was thought to be a reflection of the
overall state of health care delivery in Pakistan and decen-
tralized care [20]. This study, however, was conducted
perhaps too soon after implementation of DOTS in Paki-
stan to effectively evaluate its impact [21].
However, directly observed modes of therapy may not
always be superior to self management and the problems
of determining a priori which patients will fail to adhereBMC Medical Ethics 2004, 5 http://www.biomedcentral.com/1472-6939/5/2
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to therapy calls for reflection on both the autonomy deny-
ing aspects and potential harms of such therapy and on
the all embracing designation of all people in some
nations as requiring directly observed therapy programs
[22]. A recent Cochrane systematic review concluded that
"randomized trials provide no evidence that directly
observed therapy in low and middle income country set-
tings improves cure or treatment completion rates in
patients with tuberculosis" [23].
The results of providing a "therapeutic milieu" of mental
health techniques to both foster behavioural changes and
to increase adherence and address some other health con-
cerns of the patients in an inpatient setting were favoura-
ble. Outcomes included an increase in compliance, with
the majority of patients discharged to complete treatment
in an outpatient setting [24]. It is important to realize that
efforts are required to enhance adherence to tuberculosis
treatment, including increasing the level of community
support available to patients. A growing literature on
incentives has identified effective strategies [25]. The evi-
dence, though is far from complete and further research is
required.
Detention of TB patients is generally considered a method
of last resort [26]. A New York study found that regulatory
orders were written on 4% of 8,000 patients known to
have tuberculosis [27]. A history of leaving the hospital
against medical advice and previous noncompliance were
the strongest indicators for regulatory intervention. The
findings of a study of non-adherent TB patients in Califor-
nia indicate that detention measures target the homeless,
substance abusers, the mentally ill and people in correc-
tional facilities. 1.3% of patients were detained. Further-
more, while 84% of detained patients completed
treatment, only half of them did so within 12 months
(thus reducing the risk of developing multi-drug resistant
tuberculosis (MDRTB) and they were four times more
likely than non-detained patients to be lost to follow-up
after their release[28]. Therefore, the success of this meas-
ure is limited and may, in fact, lead to harm if detention
leads to loss of follow-up.
In summary, although there is unequivocal evidence of
the effectiveness of clinical treatment of tuberculosis, the
empirical evidence under-girding public health support
for direct observation is not overwhelmingly superior in
terms of effectiveness. Evidence of effectiveness is sparse
and becomes attenuated as one moves through more
restrictive means of ensuring treatment adherence. There
may be important and positive impacts thus far from an
internationally recommended TB control strategy on glo-
bal TB control, butthis entails recognizing the ethical
implications of imposing a strategy that lacks evidence of
superiority on vulnerable populations in societies that
may lack infrastructure toeffectively execute this strategy.
If evidence of effectiveness is to be a sine qua non of the
ethicality of public health programming, as noted in the
frameworks above, then a debate must ensue in order to
clarify support for such measures, particularly direct
observation, with the recognition that it may not be supe-
rior to self-care.
The issue here is how we conceptualize and understand
effectiveness, specifically as it relates to public health pro-
grams and the normative implications of how we under-
stand effectiveness. As evidence-based medicine attracts
increasing interest and support in the medical commu-
nity, it is important to note that central to evidence-based
medicine is the concept of an evidence hierarchy. These
hierarchies give preference to systematic reviews and
meta-analysis over non-randomized or observational
study designs, as the latter form of inquiry can be biased
particularly with regard to therapy.
The issues relating to the effectiveness of direct observa-
tion are controversial, as noted in a recent set of papers in
the British Medical Journal. Arguments have been made
suggesting that perhaps randomized controlled trials are
not the gold standard for evaluating complex programs
such as DOTS, which entail more than simply direct
observation of therapy (DOT), and that the diminished
autonomy entailed by DOTS is counterbalanced by its
focus on supporting adherence [29]. However, the added
benefit of DOTS in comparison to DOT have not been rig-
orously evaluated, and some have argued that RCT's are
not the gold standard in this domain. Volmink and Gar-
ner have argued that : "Enthusiasts make the world go
round, but there is a belief among specialists in tuberculo-
sis that it is unethical not to provide direct observation.
This attitude stifles debate and good research into alterna-
tives to direct observation is replaced by semantics." [30]
Several points of debate require clarification. Why should
more credence be given to a non-randomized trial over a
systematic review that provides a concept of quality and
has fairly precise and clear inclusion and exclusion crite-
ria? If such other studies are to be preferred to a systematic
review, then supportive arguments must be provided. Fur-
ther there are specific normative consequences to this
debate because any form of observed therapy is in princi-
ple, and in fact, autonomy denying, and the burden of
proof to deny people the right to self-management must
be correspondingly higher on those who believe studies
based on less rigorous forms of evidence. Either public
health effectiveness is defined in terms other than those
articulated by evidence-based medicine, or another rele-
vant ethical principle must be invoked to justify support
of DOT that supercedes effectiveness. The current ethical
frameworks do not provide such a trump.BMC Medical Ethics 2004, 5 http://www.biomedcentral.com/1472-6939/5/2
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Furthermore, there is a need for an open and critical dis-
cussion on the magnitude of difference or enhanced ben-
efit that is needed for one therapy to be considered
superior to another, particularly when individual liberties
are in question. Such decisions cannot be made condi-
tional on p values and confidence intervals alone, but
instead require an open discussion on how much evi-
dence and what types of evidence are required for such
limitations of autonomy to be warranted. The extent to
which those individuals and communities affected by
high level policy decisions are to be involved in the dis-
cussions as to the acceptability of varied interventions is
unclear.
Decisions to use autonomy reducing strategies in public
health may be better justified by legal standards of suffi-
cient evidence that are not necessarily commensurate with
scientific concepts of evidence articulated in evidence-
based medicine. Internationally, the Siracusa principles
can be applied to public health interventions as a means
of ensuring that restrictions of liberty and uses of coercion
for public health ends are legitimate, legal, necessary,
non-discriminatory and represent the least restrictive
means appropriate to the reasonable achievement of pub-
lic health goals [31]. Most would agree that TB control is
a legitimate social goal and that it is necessary to conduct
programs to achieve this end. Most democratic societies
have legal structures that support and sanction public
health action in the name of community protection [32].
Additionally, justifications for public health action that
rely on the potential to minimize harms rather than guar-
antee of benefits may be more appropriate, provided there
is a context of accountability and appeal [33].
Globally, there has been concern about how tuberculosis
control measures have been applied. There are reports of
increasing reliance on restrictive or coercive means to
achieve public health goals, such as legislation passed in
Russia to detain individuals for up to six months who fail
to comply with screening, diagnosis and treatment [34].
The extent to which coercive measures are used for the
control of tuberculosis around the world is unknown and
represents a priority for empirical research in this area.
Cultures vary greatly in their weight given in the balance
between community goods and individual liberties. For
example, sub-Saharan cultures have been characterized as
more broadly communitarian than North American cul-
tures [35]. Similar claims have been made for Asiatic cul-
tures [36]. Of note the Singapore Tuberculosis
Elimination program (STEP) includes the detention of
"infectious recalcitrant defaulters" as a key component of
its strategy [37]. As Doyal recently argued, coercive meas-
ures can only be justified when there is assurance that a
strategy of minimal violation of autonomy in place and
non-threatening treatment options available [38].
Equity and global imbalance
Unfortunately, many of the factors responsible for the
conditions that create tuberculosis cannot be remedied by
health care intervention. A concern for the ethics of tuber-
culosis that neglects these broader determinants of tuber-
culosis is insufficient to the task. If analysis of the
relationship between evidence and effectiveness is
restricted to the biomedical literature, it risks neglecting
broader social and economic forces relevant to the tuber-
culosis epidemic. The current ethical and evidential
frameworks frameworks under consideration do not
address such issues leaving open questions as to their
scope.
Social conditions that predispose to TB disease and its
spread are well understood: over-crowding, inadequate
housing, malnutrition, lack of timely access to medical
care and medication, to name but a few. This makes it
incumbent on public health systems to address these
issues, and inter-sectorial strategies that address these
broader determinants of health are to be encouraged
[39,40]. TB remains a scourge of marginalised popula-
tions that continue to live in conditions that increase their
vulnerability to TB, and have difficulty accessing compre-
hensive treatment and following it through to completion
or education about their illness [41]. This reflects not only
a failure of government and public health systems, but
also a violation of their fundamental rights to basic med-
ical care, as enshrined in Article 25 of the Universal Dec-
laration of Human Rights.
It should also be acknowledged that globally, TB contin-
ues to have its greatest impact on developing nations that
lack the infrastructure for even rudimentary TB control
programs. TB poses the greatest threat to persons most
likely to be unable to advocate for themselves. Their bur-
den is exacerbated by ongoing economic disparities that
are increasing dramatically [42]. These disparities make it
difficult for many nations to address the fundamental
conditions predisposing to TB without external aid, most
of which comes with specifications regarding how the
resources must be spent – including having to implement
DOT. The disease burden thus remains largest for coun-
tries less equipped to implement internationally recom-
mended strategies. Economic disparities create a situation
in which generating the resources to even attempt remedi-
ation of the medical and social determinants of tubercu-
losis is thwarted by the control that more economically
robust nations and trans-national corporations exert over
developing nations [43]. Global public health demands
an international collaborative approach and an acknowl-
edgement of the health implications of the globalized
economy, and global public health ethics demands advo-
cacy to rectify the disparities that perpetuate tuberculosis
[44]. Efforts to address TB control that ignore economicBMC Medical Ethics 2004, 5 http://www.biomedcentral.com/1472-6939/5/2
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conditions or require programs for vulnerable popula-
tions that reduce choice can be seen as further aggravating
existing inequities.
Summary
Tuberculosis is a complex but well understood disease
that raises important ethical challenges for emerging
frameworks in public health ethics. The exact role of effec-
tiveness as a criterion for the ethicality of interventions
needs greater discussion and analysis. The silence of
emerging frameworks on economic conditions contribut-
ing to the global burden of illness associated with tuber-
culosis requires remediation.
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